Latest & greatest articles for constipation

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on constipation or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on constipation and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for constipation

121. Prucalopride for the treatment of chronic constipation in women

Prucalopride for the treatment of chronic constipation in women Prucalopride for the treatment of chronic constipation in women Prucalopride for the treatment of chronic constipation in women National Institute for Health and Clinical Excellence Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation National Institute for Health and Clinical Excellence. Prucalopride (...) for the treatment of chronic constipation in women. London: National Institute for Health and Clinical Excellence (NICE). Technology Appraisal Guidance 211. 2010 Authors' conclusions Prucalopride is recommended as an option for the treatment of chronic constipation only in women for whom treatment with at least two laxatives from different classes, at the highest tolerated recommended doses for at least 6 months, has failed to provide adequate relief and invasive treatment for constipation is being considered

2010 Health Technology Assessment (HTA) Database.

122. The cost-effectiveness of macrogol 3350 compared to lactulose in the treatment of adults suffering from chronic constipation in the UK Full Text available with Trip Pro

The cost-effectiveness of macrogol 3350 compared to lactulose in the treatment of adults suffering from chronic constipation in the UK The cost-effectiveness of macrogol 3350 compared to lactulose in the treatment of adults suffering from chronic constipation in the UK The cost-effectiveness of macrogol 3350 compared to lactulose in the treatment of adults suffering from chronic constipation in the UK Taylor RR, Guest JF Record Status This is a critical abstract of an economic evaluation (...) that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The aim was to estimate the cost-effectiveness of macrogol 3350, compared with lactulose, for the treatment of chronic constipation in adults. The authors concluded that macrogol 3350 was cost-effective. The methods and the reporting of the results were good

2010 NHS Economic Evaluation Database.

123. New-onset constipation at acute stage after first stroke: incidence, risk factors, and impact on the stroke outcome Full Text available with Trip Pro

New-onset constipation at acute stage after first stroke: incidence, risk factors, and impact on the stroke outcome The prevalence of constipation after stroke varies from 30% to 60%. The incidence of new-onset constipation during the early stage of stroke remains uncertain. The present study was designed to investigate the prevalence of new-onset constipation, its risk factors, and its impact on stroke outcome in patients with their first stroke at acute stage.This is a prospective cohort (...) study of 154 patients admitted with their first stroke. New-onset constipation during the first 4 weeks of stroke was recorded, using the Rome II criteria for constipation. Demographics, characteristics of the stroke, laboratory parameters, and use of medications were evaluated as risk factors for constipation. Death, recurrent stroke, and handicap at 12 weeks were regarded as poor outcome. The impact of constipation on poor outcome was also studied.The cumulative incidence of new-onset constipation

2009 EvidenceUpdates

124. Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation--a 12-week, randomized, double-blind, placebo-controlled study (Abstract)

Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation--a 12-week, randomized, double-blind, placebo-controlled study Chronic constipation may result in disabling symptoms, is often unsatisfactorily treated by laxatives and negatively impacts quality of life (QoL).A randomized, double-blind, placebo-controlled, phase III trial to evaluate the efficacy and safety of a selective, high-affinity 5-HT(4) receptor agonist (...) , prucalopride, in patients with chronic constipation [or=3 SCBMs/week, averaged over 12 weeks. Other assessments included BM frequency, constipation-related QoL and symptoms and tolerability.Among 641 patients, significantly more patients taking prucalopride 2 or 4 mg (24%) than placebo (12%), achieved

2009 EvidenceUpdates Controlled trial quality: predicted high

125. Methylnaltrexone bromide - Constipation, Opioid-induced

Methylnaltrexone bromide - Constipation, Opioid-induced Common Drug Review CEDAC Meeting – November 19, 2008, CEDAC Reconsideration – January 21, 2009 Page 1 of 2 Notice of CEDAC Final Recommendation – January 28, 2009 © 2009 CADTH CEDAC FINAL RECOMMENDATION on RECONSIDERATION and REASONS for RECOMMENDATION METHYLNALTREXONE (Relistor ™ – Wyeth Canada) Description: Methylnaltrexone is a mu-opioid receptor antagonist approved by Health Canada for the treatment of opioid-induced constipation (...) outcome, was similar in the methylnaltrexone and placebo groups during the second week of the only two week study. Summary of Committee Considerations: The Committee considered a systematic review of two double-blind randomized controlled trials evaluating the effects of methylnaltrexone compared to placebo in palliative care patients taking other laxatives (n=287). The study population included many patients who did not report severe constipation at baseline and whose background regimens were

2009 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

126. Review: high-quality evidence on the effectiveness of laxatives for functional constipation in children is limited

Review: high-quality evidence on the effectiveness of laxatives for functional constipation in children is limited Review: high-quality evidence on the effectiveness of laxatives for functional constipation in children is limitedCommentary | Evidence-Based Nursing We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your (...) username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: high-quality evidence on the effectiveness of laxatives for functional constipation in children is limitedCommentary Article Text Treatment Review

2009 Evidence-Based Nursing

127. Currently recommended treatments of childhood constipation are not evidence based: a systematic literature review on the effect of laxative treatment and dietary measures Full Text available with Trip Pro

Currently recommended treatments of childhood constipation are not evidence based: a systematic literature review on the effect of laxative treatment and dietary measures Currently recommended treatments of childhood constipation are not evidence based: a systematic literature review on the effect of laxative treatment and dietary measures Currently recommended treatments of childhood constipation are not evidence based: a systematic literature review on the effect of laxative treatment (...) and dietary measures Pijpers MA, Tabbers MM, Benninga MA, Berger MY CRD summary The review found that there was insufficient evidence to show that laxatives were superior to placebo for treating constipation in children and that no one laxative could be recommended over any other. Although the review was limited in some respects, in particular the failure to address statistical heterogeneity, the authors' cautious conclusions appear justified. Authors' objectives To determine the effectiveness

2009 DARE.

128. Biofeedback therapy in fecal incontinence and constipation Full Text available with Trip Pro

Biofeedback therapy in fecal incontinence and constipation Biofeedback therapy in fecal incontinence and constipation Biofeedback therapy in fecal incontinence and constipation Enck P, van der Voort IR, Klosterhalfen S CRD summary The authors concluded that there was evidence of a substantial therapeutic effect of biofeedback therapy for constipation due to pelvic floor dyssynergia, but lack of evidence for biofeedback therapy for incontinence. There were a number of limitations to this review (...) . In particular, the review did not report data specific to pelvic floor dyssynergia, so these conclusions may not be reliable. Authors' objectives To evaluate the efficacy of biofeedback therapy for the treatment of constipation and faecal incontinence. Searching PubMed was searched for studies published in English between 1980 and 2008; search terms were reported. In addition, reference lists in identified articles, reviews and meta-analyses were screened. Study selection Randomised controlled trials (RCTs

2009 DARE.

129. [Methylnaltrexone for opioid-induced constipation in cancer treatment]

[Methylnaltrexone for opioid-induced constipation in cancer treatment] Metylnaltrekson ved forstoppelse i kreftbehandling [Methylnaltrexone for opioid-induced constipation in cancer treatment] Metylnaltrekson ved forstoppelse i kreftbehandling [Methylnaltrexone for opioid-induced constipation in cancer treatment] Movik E, Ringerike T, Linnestad KK, Hofmann, B, Harboe I, Klemp M Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA (...) . No evaluation of the quality of this assessment has been made for the HTA database. Citation Movik E, Ringerike T, Linnestad KK, Hofmann, B, Harboe I, Klemp M. Metylnaltrekson ved forstoppelse i kreftbehandling. [Methylnaltrexone for opioid-induced constipation in cancer treatment] Oslo: Norwegian Knowledge Centre for the Health Services (NOKC). Report from NOKC nr 23 - 2009.. 2009 Authors' conclusions Our review suggests that methylnaltrexone was more effective than placebo in terms of time to laxation

2009 Health Technology Assessment (HTA) Database.

130. Tegaserod for female patients suffering from IBS with mixed bowel habits or constipation: a randomized controlled trial Full Text available with Trip Pro

Tegaserod for female patients suffering from IBS with mixed bowel habits or constipation: a randomized controlled trial Though the greatest proportion of irritable bowel syndrome (IBS) patients report a mixed bowel pattern (IBS-Mixed), no available therapies have been rigorously evaluated in this subgroup. This study aimed to evaluate the efficacy and safety of the 5-HT(4) agonist tegaserod in women with IBS-Mixed and IBS with constipation (IBS-C).This prospective, double-blind, randomized

2008 EvidenceUpdates Controlled trial quality: predicted high

131. Methylnaltrexone for opioid-induced constipation in advanced illness. Full Text available with Trip Pro

Methylnaltrexone for opioid-induced constipation in advanced illness. Constipation is a distressing side effect of opioid treatment. As a quaternary amine, methylnaltrexone, a mu-opioid-receptor antagonist, has restricted ability to cross the blood-brain barrier. We investigated the safety and efficacy of subcutaneous methylnaltrexone for treating opioid-induced constipation in patients with advanced illness.A total of 133 patients who had received opioids for 2 or more weeks and who had (...) received stable doses of opioids and laxatives for 3 or more days without relief of opioid-induced constipation were randomly assigned to receive subcutaneous methylnaltrexone (at a dose of 0.15 mg per kilogram of body weight) or placebo every other day for 2 weeks. Coprimary outcomes were laxation (defecation) within 4 hours after the first dose of the study drug and laxation within 4 hours after two or more of the first four doses. Patients who completed this phase were eligible to enter a 3-month

2008 NEJM Controlled trial quality: predicted high

132. A placebo-controlled trial of prucalopride for severe chronic constipation. (Abstract)

A placebo-controlled trial of prucalopride for severe chronic constipation. In this 12-week trial, we aimed to determine the efficacy of prucalopride, a selective, high-affinity 5-hydroxytryptamine4 receptor agonist, in patients with severe chronic constipation.In our multicenter, randomized, placebo-controlled, parallel-group, phase 3 trial, patients with severe chronic constipation (< or =2 spontaneous, complete bowel movements per week) received placebo or 2 or 4 mg of prucalopride, once (...) efficacy end points, including patients' satisfaction with their bowel function and treatment and their perception of the severity of their constipation symptoms, were significantly improved with the use of 2 or 4 mg of prucalopride as compared with placebo, at week 12. The most frequent treatment-related adverse events were headache and abdominal pain. There were no significant cardiovascular effects of treatment.Over 12 weeks, prucalopride significantly improved bowel function and reduced

2008 NEJM Controlled trial quality: predicted high

133. Methylnaltrexone reduced opioid-induced constipation in patients with terminal illness

Methylnaltrexone reduced opioid-induced constipation in patients with terminal illness Methylnaltrexone reduced opioid-induced constipation in patients with terminal illness | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers (...) of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Methylnaltrexone reduced opioid-induced constipation in patients with terminal illness Article Text Therapeutics Methylnaltrexone reduced opioid-induced constipation in patients with terminal illness Statistics from

2008 Evidence-Based Medicine

134. Daily polyethylene glycol over 6 months was effective for chronic constipation

Daily polyethylene glycol over 6 months was effective for chronic constipation Daily polyethylene glycol over 6 months was effective for chronic constipation | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts (...) Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Daily polyethylene glycol over 6 months was effective for chronic constipation Article Text Therapeutics Daily polyethylene glycol over 6 months was effective for chronic constipation Statistics from Altmetric.com Request Permissions

2008 Evidence-Based Medicine

135. Effects of 5-hydroxytryptamine (serotonin) type 3 antagonists on symptom relief and constipation in nonconstipated irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials

Effects of 5-hydroxytryptamine (serotonin) type 3 antagonists on symptom relief and constipation in nonconstipated irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2008 DARE.

136. Cost-effectiveness of macrogol 4000 compared to lactulose in the treatment of chronic functional constipation in the UK

Cost-effectiveness of macrogol 4000 compared to lactulose in the treatment of chronic functional constipation in the UK Cost-effectiveness of macrogol 4000 compared to lactulose in the treatment of chronic functional constipation in the UK Cost-effectiveness of macrogol 4000 compared to lactulose in the treatment of chronic functional constipation in the UK Guest J F, Clegg J P, Helter M T Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion (...) on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to examine the cost-effectiveness of macrogol 4000 compared with lactulose for the treatment of chronic functional constipation in adult patients. The authors concluded that macrogol 4000 was a cost-effective treatment from the perspective of the British National Health Service

2008 NHS Economic Evaluation Database.

137. Clinical trial: renzapride therapy for constipation-predominant irritable bowel syndrome--multicentre, randomized, placebo-controlled, double-blind study in primary healthcare setting (Abstract)

Clinical trial: renzapride therapy for constipation-predominant irritable bowel syndrome--multicentre, randomized, placebo-controlled, double-blind study in primary healthcare setting Relatively few pharmacological treatment options are available for treating patients with irritable bowel syndrome. New and effective medicines are urgently required.To identify an appropriate dosage of renzapride (a 5-HT(4) receptor full agonist/5-HT(3) receptor antagonist) to treat abdominal pain/discomfort (...) in patients with constipation-predominant irritable bowel syndrome.In this randomized, placebo-controlled, phase IIb study in the primary care setting, men and women were randomized to placebo or renzapride (1, 2 or 4 mg/day) for 12 weeks. The primary outcome measure was patient self-assessed relief of abdominal pain/discomfort during weeks 5-12. Secondary efficacy measures included patients' assessment of their bowel habits, stool consistency and quality of life.Although there were no statistically

2008 EvidenceUpdates Controlled trial quality: predicted high

138. Behavioral therapy for childhood constipation: a randomized, controlled trial Full Text available with Trip Pro

Behavioral therapy for childhood constipation: a randomized, controlled trial It has been suggested that the addition of behavioral interventions to laxative therapy improves continence in children with functional fecal incontinence associated with constipation. Our aim was to evaluate the clinical effectiveness of behavioral therapy with laxatives compared with conventional treatment in treating functional constipation in childhood.In this randomized, controlled trial conducted in a tertiary (...) hospital in The Netherlands, 134 children aged 4 to 18 years with functional constipation were randomly assigned to 22 weeks (12 visits) of either behavioral therapy or conventional treatment. Primary outcomes were defecation frequency, fecal incontinence frequency, and success rate. Success was defined as defecation frequency of > or = 3 times per week and fecal incontinence frequency of < or = 1 times per 2 weeks irrespective of laxative use. Secondary outcomes were stool-withholding behavior

2008 EvidenceUpdates Controlled trial quality: predicted high

139. Sacral nerve stimulation for faecal incontinence and constipation in adults. (Abstract)

Sacral nerve stimulation for faecal incontinence and constipation in adults. Faecal incontinence and constipation are disabling conditions that reduce quality of life. If conservative treatment fails, one option is sacral nerve stimulation (SNS), a minimally invasive technique allowing modulation of the nerves and muscles of the pelvic floor and hindgut.To assess the effects of SNS for faecal incontinence and constipation in adults.We searched the Cochrane Incontinence Group Specialised Trials (...) Register (searched 24 April 2007) and the reference lists of relevant articles.All randomised or quasi-randomised trials assessing the effects of SNS for faecal incontinence or constipation in adults.Two review authors independently screened the search results, assessed the methodological quality of the included studies, and undertook data extraction.Three crossover studies were included. Two, enrolling 34 (Leroi) and two participants (Vaizey), assessed the effects of SNS for faecal incontinence

2007 Cochrane

140. Methylnatrexone for opioid induced constipation in advanced illness and palliative care: horizon scanning technology briefing

Methylnatrexone for opioid induced constipation in advanced illness and palliative care: horizon scanning technology briefing Methylnatrexone for opioid induced constipation in advanced illness and palliative care: horizon scanning technology briefing Methylnatrexone for opioid induced constipation in advanced illness and palliative care: horizon scanning technology briefing National Horizon Scanning Centre Record Status This is a bibliographic record of a published health technology assessment (...) from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation National Horizon Scanning Centre. Methylnatrexone for opioid induced constipation in advanced illness and palliative care: horizon scanning technology briefing. Birmingham: National Horizon Scanning Centre (NHSC). 2007 Authors' objectives This study examines the use of Methylnatrexone for opioid induced constipation in advanced illness and palliative care. Project page URL Indexing

2007 Health Technology Assessment (HTA) Database.